7 results
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in one…
The primary objective of this study is to determine if neuroinflammation is present in patients with mild traumatic brain injury, using [11C]-PK11195 PET. The secondary objective is to determine if there is a correlation between [11C]-PK11195…
The primary objective is to determine whether neuroinflammation is present in subjects who have been exposed to chronic repetitive head injury during Muay Thai boxing, using [11C]-PK11195 PET.
Primary Objective: * To confirm the safety profile of plerixafor to mobilise stem cells when used in patients with lymphoma or MM who are eligible to undergo treatment with an autologous haematopoietic stem cell transplantSecondary Objectives:* To…
Primary study objectives:· To determine the safety [(adverse event profile, dose-limiting toxicity (DLT) and maximum tolerated dose (MTD)] of JNJ-26483327in male and female subjects with cancer.· To determine the pharmacokinetics (PK) of JNJ-…
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
To demonstrate that Plerixafor is able to reduce the need for invasive mechanical ventilation or death in severe COVID-19 patients admitted in Intensive Care Unit (ICU)